<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339000</url>
  </required_header>
  <id_info>
    <org_study_id>110146</org_study_id>
    <secondary_id>11-C-0146</secondary_id>
    <nct_id>NCT01339000</nct_id>
  </id_info>
  <brief_title>Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy</brief_title>
  <official_title>A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system.&#xD;
      But it can also become weaker because of aging. Interleukin (IL)-7, a molecule produced&#xD;
      naturally in the body, can help improve the function of the immune system. Researchers want&#xD;
      to study the effects of IL-7 on immune system function in two different groups of older&#xD;
      people. One group will be people who have received vaccines before IL-7. The other group will&#xD;
      be people who have received Vaccines after IL-7.&#xD;
&#xD;
      Objectives: To evaluate the effect of IL-7 on the immune system responses to vaccines in&#xD;
      older people following chemotherapy.&#xD;
&#xD;
      Eligibility: People at least 60 years of age who have recently finished chemotherapy for&#xD;
      breast, colon, or bladder cancer.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  People in the study will be screened with a physical examination, medical history, and&#xD;
           blood tests. Other screening tests, such as tumor imaging, may also need to be&#xD;
           performed.&#xD;
&#xD;
        -  Everyone will receive a series of five different vaccines commonly used to prevent&#xD;
           diseases. We will compare the responses of people in Sequence 1 who will receive&#xD;
           vaccines before IL-7 with the responses of people in Sequence 2 who received the same&#xD;
           vaccines after IL-7.&#xD;
&#xD;
        -  The vaccines will be given randomly in two Arms at different times.&#xD;
&#xD;
             -  Arm 1: diphtheria and tetanus, polio, pneumonia (with two booster shots), hepatitis&#xD;
                B (with two booster shots), and hepatitis A (with one booster shot),&#xD;
&#xD;
             -  Arm 2: hepatitis A (with one booster shot), hepatitis B (with two booster shots),&#xD;
                pneumococcal (with two booster shots), diphtheria and tetanus, polio, pneumonia&#xD;
                (with two booster shots)&#xD;
&#xD;
        -  There are 5 vaccines to be given to each subject, following one of two randomly assigned&#xD;
           sequences of vaccine administration (Sequence 1 or Sequence 2).&#xD;
&#xD;
        -  The first vaccine arm contains the two diphtheria protein containing vaccines tetanus&#xD;
           and diphtheria (Td) and pneumococcal conjugate 13 (PCV13) and polio. The second vaccine&#xD;
           arm contains the Hepatitis A and Hepatitis B vaccines. Subjects will either get tetanus,&#xD;
           diphtheria, polio, and pneumonia vaccines before IL-7 therapy (Sequence 1) or hepatitis&#xD;
           A and hepatitis B vaccines before IL-7 therapy (Sequence 2). The response to vaccines&#xD;
           will be evaluated 4 weeks after vaccination. This will be followed by IL-7 therapy, then&#xD;
           administration of the other group of vaccines. Therefore, subjects on both arms will&#xD;
           receive the same set of vaccines, just at different times with respect to IL-7 therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
        -  Interleukin-7 is a homeostatic cytokine with a critical role in lymphoid homeostasis&#xD;
           through which it exerts its immune-restorative effects, particularly re-expansion of the&#xD;
           naive and memory T cell subsets.&#xD;
&#xD;
        -  The clinical implications of the kinetics, nature and extent of immune reconstitution&#xD;
           defects following standard or ablative chemotherapy in older adults with cancer (in&#xD;
           particular the lack of reconstitution of large pools naive T cell with broad repertoire&#xD;
           diversity and of memory T cells) are not fully appreciated.&#xD;
&#xD;
        -  As chemotherapy often induces only temporary complete or partial disease responses but&#xD;
           no cure, candidates for novel immunotherapy strategies may be significantly impeded in&#xD;
           their responses to active immunotherapy attempts, the therapeutic potential of which may&#xD;
           be misjudged or altogether overlooked.&#xD;
&#xD;
        -  Recombinant human interleukin-7 (rhIL-7) may play a role in immune reconstitution and&#xD;
           immune enhancement in various circumstances of immune insufficiency in older individuals&#xD;
           following chemotherapy or in the context of enhancing cancer immunotherapy or during&#xD;
           immune senescence.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      - Evaluate and quantify the impact of interleukin-7 (CYT107) therapy on specific immune&#xD;
      responses to each vaccine (in particular to neo antigens) in older subjects following&#xD;
      chemotherapy.&#xD;
&#xD;
      ELIGIBILITY:&#xD;
&#xD;
        -  Adults over the age of 60.&#xD;
&#xD;
        -  Diagnosis of non metastatic breast, bladder or colorectal cancer following adjuvant /&#xD;
           neo-adjuvant chemotherapy.&#xD;
&#xD;
        -  Completed a treatment with chemotherapy a minimum of 4 weeks prior to entry.&#xD;
&#xD;
        -  Reasonable expectation that no chemotherapy will be given in the subsequent 6 months.&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
        -  Subjects will be enrolled following the specific therapy for their respective diseases.&#xD;
&#xD;
        -  Subjects will undergo immunizations with various antigens, randomized to be administered&#xD;
           either before or after treatment with CYT107&#xD;
&#xD;
        -  The vaccines, randomly assigned to be administered before CYT107 therapy are&#xD;
           administered four weeks before the start of CYT107 therapy.&#xD;
&#xD;
        -  CYT107 is administered once a week for 3 doses (20 microg/kg/dose) via intramuscular&#xD;
           route (IM)&#xD;
&#xD;
        -  The vaccines, randomly assigned to be administered after CYT107 therapy are administered&#xD;
           17 days after the first dose of CYT107 therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company supplying drug declared bankruptcy, thus there was no drug supply.&#xD;
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on the T Cell Receptor Diversity in Older Subjects Following Chemotherapy</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Effects of Interleukin-7 (CYT107) Therapy on the Quality of T Cell Specific Responses by Multiparameter Flow Cytometry</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Based on the First Two Primary Objectives, Consider and Discuss the Need for Larger Studies to Evaluate the Potential Benefit of Interleukin-7 (CYT107) Administration in a Broad, Mass Protection Strategy for an Aging Population</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycosylated Recombinant Human Interleukin-7</intervention_name>
    <description>Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria/Tetanus Vaccine</intervention_name>
    <description>Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Polio Vaccine</intervention_name>
    <description>Polio Vaccine will be administered according to the randomized schedule per protocol.</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Vaccine</intervention_name>
    <description>Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A Vaccine</intervention_name>
    <description>Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine</intervention_name>
    <description>Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
    <arm_group_label>Arm A -Sequence 1 Immunizations</arm_group_label>
    <arm_group_label>Arm B - Sequence 2 Immunizations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Adults over the age of 60&#xD;
&#xD;
          -  Documentation of positive diagnosis for any of the following:&#xD;
&#xD;
               -  Non metastatic breast carcinoma following neo-adjuvant chemotherapy and&#xD;
                  appropriate surgery or following adjuvant radio / chemotherapy.&#xD;
&#xD;
               -  Stage II or III colon carcinoma following appropriate surgery and adjuvant&#xD;
                  chemotherapy or following appropriate neoadjuvant chemoradiation/surgery and&#xD;
                  adjuvant chemotherapy.&#xD;
&#xD;
               -  Stage II bladder carcinoma following neo-adjuvant chemotherapy and appropriate&#xD;
                  surgery or following adjuvant chemotherapy. Patients with recurrent tumors are&#xD;
                  not eligible.&#xD;
&#xD;
               -  Appropriate therapy for each disease must be consistent with the latest National&#xD;
                  Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology&#xD;
                  available at the web site:&#xD;
                  http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&#xD;
&#xD;
               -  Completed cancer specific therapy (including surgery, radiotherapy and/or&#xD;
                  chemotherapy) a minimum of 4 weeks prior to entry. (Subjects with hormone&#xD;
                  receptor positive breast carcinoma maintained on hormonal therapy following&#xD;
                  chemotherapy and radiation are eligible).&#xD;
&#xD;
          -  Completed cancer specific therapy at most 6 months prior to entry.&#xD;
&#xD;
          -  Reasonable expectation that no chemotherapy will be given in the subsequent 6 months&#xD;
             (Principal Investigators (PIs) discretion).&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          -  Bilirubin &lt; 1.5.&#xD;
&#xD;
          -  Absolute Neutrophil Count greater than l000 / mm(3).&#xD;
&#xD;
          -  Platelet count greater than 75K.&#xD;
&#xD;
          -  International normalized ratio (INR)/partial thromboplastin time (PTT) within 1.5&#xD;
             times upper limit of normal (Common Terminology Criteria in Adverse Events (CTCAE) 4.0&#xD;
             grade 1 abnormality is acceptable)&#xD;
&#xD;
          -  Serum creatinine within 1.5 times upper limit of normal (CTCAE 4.0 grade 1 abnormality&#xD;
             is acceptable)&#xD;
&#xD;
          -  Creatine phosphokinase (CPK) within 2.5 times upper limit of normal (CTCAE 4.0 grade 1&#xD;
             abnormality is acceptable)&#xD;
&#xD;
          -  Serum albumin greater or equal to 3g/dl (CTCAE 4.0 grade 1 abnormality is acceptable)&#xD;
&#xD;
          -  Serum electrolytes within normal limits (CTCAE 4.0 grade 1 abnormality is acceptable)&#xD;
&#xD;
          -  Karnofsky performance status greater or equal to 70%.&#xD;
&#xD;
        EXCLUSION CRITERIA FOR ALL PARTICIPANTS:&#xD;
&#xD;
          -  Significant heart disease defined as:&#xD;
&#xD;
               -  Significant coronary arterial disease&#xD;
&#xD;
               -  myocardial infarction in the last 6 months, angina in the previous 3 months,&#xD;
&#xD;
               -  Troponin elevation at level of myocardial infarction as defined by the&#xD;
                  manufacturer&#xD;
&#xD;
               -  Ischemic changes on electrocardiogram (ECG)&#xD;
&#xD;
               -  Atrio-ventricular block greater than 1st degree, in absence of pacemaker,&#xD;
&#xD;
               -  Corrected QT interval (QTc) greater than 480ms (CTCAE 4.0 grade 1 abnormality is&#xD;
                  acceptable),&#xD;
&#xD;
               -  History of ventricular arrhythmia,&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction below the institutional limit of normal,&#xD;
&#xD;
          -  Positive serology for human T-lymphotropic viruses, type 1 (HTLV I), human&#xD;
             immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection&#xD;
             including a positive hepatitis B serology indicative of previous immunization (i.e.&#xD;
             hepatitis B surface antibody (HBs Ab) positive and hepatitis B core antibody (HBc Ab)&#xD;
             negative)&#xD;
&#xD;
          -  History of autoimmune disease: patients with vitiligo or endocrine disease controlled&#xD;
             by replacement therapy including, diabetes, thyroid and adrenal disease may be&#xD;
             enrolled&#xD;
&#xD;
          -  Patients requiring chronic immunosuppressive therapy (including corticosteroids) for&#xD;
             any medical condition,&#xD;
&#xD;
          -  Splenomegaly or history of proliferative hematologic disease&#xD;
&#xD;
          -  Prior allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation&#xD;
&#xD;
          -  Inability or refusal to practice contraception during therapy (as physiologically&#xD;
             relevant)&#xD;
&#xD;
          -  History of medical or psychiatric disease which, in the view of the principal&#xD;
             investigator, would preclude safe treatment&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Serious bleeding diathesis or those who are on therapeutic anticoagulation&#xD;
&#xD;
          -  Previous exposure to Hepatitis A or B vaccines&#xD;
&#xD;
        Patients who received a tetanus and diphtheria (Td) or tetanus, diphtheria- acelluar,&#xD;
        pertussis (Tdap) immunization in the previous 5 years,&#xD;
&#xD;
          -  History of anaphylaxis or serious allergic reactions to previous administration of any&#xD;
             of the vaccines&#xD;
&#xD;
          -  Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymixin&#xD;
             B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast&#xD;
&#xD;
          -  Patients who had received one or more doses of the pneumococcal polysaccharide vaccine&#xD;
             23 (PPSV23) vaccine in the previous 12 months&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald E Gress, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>BOWMAN BU Jr, PATNODE RA. NEUTRALIZATION OF BACTERIOPHAGE PHI-X174 BY SPECIFIC ANTISERUM. J Immunol. 1964 Apr;92:507-14.</citation>
    <PMID>14139020</PMID>
  </reference>
  <reference>
    <citation>Finkelstein MS, Uhr JW. Antibody formation. V. The avidity of gamma-M and gamma-G guinea pig antibodies to bacteriophage phi-x 174. J Immunol. 1966 Nov;97(5):565-76.</citation>
    <PMID>5926449</PMID>
  </reference>
  <reference>
    <citation>ROLFE U, SINSHEIMER RL. ANTIGENS OF BACTERIOPHAGE PHI-X174. J Immunol. 1965 Jan;94:18-21.</citation>
    <PMID>14253517</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <results_first_submitted>May 16, 2016</results_first_submitted>
  <results_first_submitted_qc>May 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2016</results_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Ronald Gress, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Immunization</keyword>
  <keyword>Immunocompromised Host</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A - Sequence 1 Immunizations</title>
          <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
        <group group_id="P2">
          <title>Arm B - Sequence 2 Immunizations</title>
          <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">The patient received day 1, 29, 36, 43, 50, and 57 vaccines but did not receive interleukin-7 (IL-7)</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study closed due to lack of drug supply</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A - Sequence 1 Immunizations</title>
          <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
        <group group_id="B2">
          <title>Arm B - Sequence 2 Immunizations</title>
          <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="0"/>
                    <measurement group_id="B3" value="61.3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy</title>
        <time_frame>8 weeks</time_frame>
        <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Sequence 1 Immunizations</title>
            <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Sequence 2 Immunizations</title>
            <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy</title>
          <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on the T Cell Receptor Diversity in Older Subjects Following Chemotherapy</title>
        <time_frame>10 weeks</time_frame>
        <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A -Sequence 1 Immunizations</title>
            <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Sequence 2 Immunizations</title>
            <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on the T Cell Receptor Diversity in Older Subjects Following Chemotherapy</title>
          <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Effects of Interleukin-7 (CYT107) Therapy on the Quality of T Cell Specific Responses by Multiparameter Flow Cytometry</title>
        <time_frame>8 weeks</time_frame>
        <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Sequence 1 Immunizations</title>
            <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Sequence 2 Immunizations</title>
            <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Effects of Interleukin-7 (CYT107) Therapy on the Quality of T Cell Specific Responses by Multiparameter Flow Cytometry</title>
          <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Based on the First Two Primary Objectives, Consider and Discuss the Need for Larger Studies to Evaluate the Potential Benefit of Interleukin-7 (CYT107) Administration in a Broad, Mass Protection Strategy for an Aging Population</title>
        <time_frame>1 year</time_frame>
        <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Sequence 1 Immunizationa</title>
            <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Sequence 2 Immunizations</title>
            <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Based on the First Two Primary Objectives, Consider and Discuss the Need for Larger Studies to Evaluate the Potential Benefit of Interleukin-7 (CYT107) Administration in a Broad, Mass Protection Strategy for an Aging Population</title>
          <population>Insufficient data was collected for any analysis to take place. The study was closed due to lack of drug supply.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Sequence 1 Immunizations</title>
            <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Sequence Immunizations</title>
            <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A - Sequence 1 Immunizations</title>
          <description>Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
        <group group_id="E2">
          <title>Arm B - Sequence 2 Immunizations</title>
          <description>Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7&#xD;
Glycosylated Recombinant Human Interleukin-7: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection&#xD;
Diphtheria/Tetanus Vaccine: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.&#xD;
Polio Vaccine: Polio Vaccine will be administered according to the randomized schedule per protocol.&#xD;
Pneumococcal Vaccine: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis A Vaccine: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.&#xD;
Hepatitis B Vaccine: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The company supplying interleukin-7 (IL-7) declared bankruptcy, thus the study was closed due to lack of drug supply.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ronald Gress</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-496-1791</phone>
      <email>gressr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

